NAVB - Navidea biopharmaceuticals secures additional bridge loan funding of 1M
- Navidea Biopharmaceuticals ( NYSE: NAVB ) largest shareholder and Board Vice Chair John K. Scott, funded an additional $1M under the secured bridge loan that was executed on April 10, 2022 .
- “We are delighted to have the continued funding in place from Mr. Scott to keep our Phase 3 and R&D efforts moving forward.” said Dr. Michael Rosol, Chief Medical Officer
For further details see:
Navidea biopharmaceuticals secures additional bridge loan funding of 1M